Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Latest
Popular

Custirsen shows no survival benefit in metastatic prostate cancer

Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France
Custirsen shows no survival benefit in metastatic prostate cancer ( Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France )
10 Oct 2016

Benefits of adjuvant chemo for soft tissue sarcoma patients

Dr Alessandro Gronchi - National Cancer Institute, Milan, Italy
Benefits of adjuvant chemo for soft tissue sarcoma patients ( Dr Alessandro Gronchi - National Cancer Institute, Milan, Italy )
10 Oct 2016

Significant survival gains for neoadjuvant chemotherapy for high risk soft tissue sarcoma

Dr Alessandro Gronchi - National Cancer Institute, Milan, Italy
Significant survival gains for neoadjuvant chemotherapy for high risk soft tissue sarcoma ( Dr Alessandro Gronchi - National Cancer Institute, Milan, Italy )
10 Oct 2016

Cabozantinib over sunitinib for metastatic renal cell carcinoma

Dr Toni Choueiri - Dana Farber Cancer Institute, Boston, USA
Cabozantinib over sunitinib for metastatic renal cell carcinoma ( Dr Toni Choueiri - Dana Farber Cancer Institute, Boston, USA )
10 Oct 2016

Negative trial results of custirsen for metastatic prostate cancer

Prof Karim Fizazi - Cancer Medicine at the Institut Gustave Roussy, Villejuif, France
Negative trial results of custirsen for metastatic prostate cancer ( Prof Karim Fizazi - Cancer Medicine at the Institut Gustave Roussy, Villejuif, France )
10 Oct 2016

Cabozantinib improves PFS in metastatic renal cell carcinoma

Dr Toni Choueiri - Dana Farber Cancer Institute, Boston, USA
Cabozantinib improves PFS in metastatic renal cell carcinoma ( Dr Toni Choueiri - Dana Farber Cancer Institute, Boston, USA )
10 Oct 2016

Advances for NSCLC in review

Dr Stefan Zimmermann - Hôpital Fribourgeois, Fribourg, Switzerland
Advances for NSCLC in review ( Dr Stefan Zimmermann - Hôpital Fribourgeois, Fribourg, Switzerland )
9 Oct 2016

Ceritinib following crizotinib relapse for ALK positive NSCLC

Dr Giorgio Scagliotti - University of Turin, Turin, Italy
Ceritinib following crizotinib relapse for ALK positive NSCLC ( Dr Giorgio Scagliotti - University of Turin, Turin, Italy )
9 Oct 2016

Atezolizumab v docetaxel for NSCLC: results from the OAK trial

Dr Fabrice Barlesi - Hôpital Nord, Marseille, France
Atezolizumab v docetaxel for NSCLC: results from the OAK trial ( Dr Fabrice Barlesi - Hôpital Nord, Marseille, France )
9 Oct 2016

Significant survival gains with atezolizumab for NSCLC

Dr Fabrice Barlesi - Hôpital Nord, Marseille, France
Significant survival gains with atezolizumab for NSCLC ( Dr Fabrice Barlesi - Hôpital Nord, Marseille, France )
9 Oct 2016

Pembrolizumab new option for firstline treatment of advanced lung cancer with high PDL-1 expression

Dr Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany
Pembrolizumab new option for firstline treatment of advanced lung cancer with high PDL-1 expression ( Dr Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany )
9 Oct 2016

Pembrolizumab plus chemo as firstline therapy for NSCLC

Dr Corey Langer - University of Pennsylvania, Philadelphia, USA
Pembrolizumab plus chemo as firstline therapy for NSCLC ( Dr Corey Langer - University of Pennsylvania, Philadelphia, USA )
9 Oct 2016

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation